UroGen Pharma Expands Leadership Team, Appoints Industry Veterans Jeffrey Bova as Vice President of Commercial and James Ottinger as Vice President of Regulatory Affairs
October 26, 2017 08:30 ET
|
UroGen Pharma Ltd.
RA’ANANA, Israel, and NEW YORK, Oct. 26, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
UroGen Pharma Strengthens Management Team with the Appointment of Paul Chu as Vice President of Business Development
September 06, 2017 08:30 ET
|
UroGen Pharma
RA'ANANA, Israel, and NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in...
UroGen Pharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
September 05, 2017 08:30 ET
|
UroGen Pharma
RA'ANANA, Israel, and NEW YORK, Sept. 05, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in...
UroGen Pharma Receives FDA Fast Track Designation for MitoGel™ for the Treatment of Upper Tract Urothelial Carcinoma (UTUC)
August 29, 2017 08:30 ET
|
UroGen Pharma
RA’ANANA, Israel and NEW YORK, Aug. 29, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
UroGen Pharma Reports Second Quarter 2017 Financial Results and Recent Corporate Developments
August 14, 2017 16:05 ET
|
UroGen Pharma
Completed Initial Public Offering Raising $66.9 Million in Gross Proceeds Continuing Enrollment of Patients in the Phase 3 OLYMPUS Clinical Trial of MitoGel™ for the Treatment of Low-Grade Upper...
Investigational New Drug Application for RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder Submitted to FDA by Allergan
July 19, 2017 08:30 ET
|
UroGen Pharma
RA’ANANA, Israel, and NEW YORK, July 19, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
UroGen Pharma to Ring the Nasdaq Stock Market Opening Bell
June 02, 2017 08:00 ET
|
UroGen Pharma
RA’ANANA, Israel and NEW YORK, June 02, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address...
UroGen Pharma to Present at the Jefferies 2017 Global Healthcare Conference
May 30, 2017 08:00 ET
|
UroGen Pharma
RA’ANANA, Israel and NEW YORK, May 30, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address...
UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors
May 16, 2017 08:15 ET
|
UroGen Pharma
RA’ANANA, Israel and NEW YORK, May 16, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address...
UroGen Pharma Announces Two Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association 2017 Annual Meeting
May 11, 2017 08:00 ET
|
UroGen Pharma
RA’ANANA, Israel, May 11, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in...